A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Brief description of study

The purpose of the study is to determine the efficacy and safety of Pembrolizumab plus investigational Agents in combination with etoposide and Cisplatin or Carboplatin for the first-line treatment of participants with extensive-stage Small Cell Lung Cancer. We want to know the complete response or partial response as well as the 6-month progression free survival: survival without documented disease progression or death due to any cause at 6 months after randomization. The study drugs MK-5890, E7080, MK-4830, and Pembrolizumab are investigational in this study, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.

Clinical Study Identifier: s20-01982
ClinicalTrials.gov Identifier: NCT04924101
Principal Investigator: Marissa Rybstein.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.